AbbVie, Eli Lilly and Gilead Hit Record Highs as Tech Selloff Reshuffles Money

By Olivia Hart

Shares of AbbVie, Eli Lilly and Gilead Sciences are trading at or near record highs, according to the market report — a striking turn for a sector that spent much of the past two years watching capital flood into technology instead.

The report attributes the move to a broader rotation: investors pushed out of technology by the selloff are moving money toward pharmaceutical stocks, which they treat as safer bets. That is the entire stated thesis. Three companies, one direction, one driver.

Which companies are at record levels?

The report names exactly three: AbbVie, Eli Lilly and Gilead Sciences. It says their shares trade "at or near record highs" — wording worth pausing over. "At or near" is not the same as "at." Some of these stocks may sit a fraction below their peaks; the phrasing does not tell us which, or by how much.

That distinction matters for readers deciding whether the rally has already run. A stock at its high is a different proposition from one still climbing back toward it.

The three names also span very different businesses — AbbVie in immunology and aesthetics, Eli Lilly in diabetes and obesity drugs, Gilead in antivirals and oncology. The report does not rank them, size their individual moves, or say whether all three hit records on the same day.

What is driving the rotation?

The stated driver is the technology selloff. Investors, the report says, are seeking "safer bets" — pharma's traditional label in risk-off markets, because drug demand does not swing with the economic cycle the way advertising or hardware spending does.

Note what the report does not claim. It offers no fund-flow figures, no percentage gain for any stock, and no analyst quotation. The safety argument is presented as market interpretation, not as a stated position by any named investor or institution. Readers should treat it as the prevailing narrative rather than verified cause and effect.

Takeaway: the rally is real, but the explanation rests on one sentence of attribution.

How solid is the safety case?

Skeptically, "safer" deserves scrutiny the report does not supply. Pharmaceutical equities carry their own risks — patent cliffs, drug-pricing politics, pipeline failures — none of which vanish because technology shares are falling. A rotation trade can also reverse quickly if tech sentiment stabilizes, pulling money back out of defensive names as fast as it arrived.

The report gives no valuation context. Record highs on depressed earnings multiples mean something different from record highs on stretched ones. Without those figures, readers cannot judge how much cushion, if any, exists under the move.

Takeaway: safer is relative, and the source stops short of testing it.

What comes next?

The durability of the pharma rally depends on the variable the report identifies as its trigger: whether the technology selloff deepens or fades. If investors rotate back, record-setting defensives are typically the first place money exits.